- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Some anticonvulsants may raise suicide risk
Anticonvulsant agents have important therapeutic benefits. However, both the healthcare provider and patient need to remain cognizant of associated risks, according to results of a study published in the April 13, 2010, edition of the Journal of the American Medical Association.
Anticonvulsant agents have important therapeutic benefits. However, both the healthcare provider and patient need to remain cognizant of associated risks, according to results of a study published in the April 13, 2010, edition of the Journal of the American Medical Association.
In the cohort study, researchers evaluated the risk of suicidal acts and combined suicidal acts or violent death associated with individual anticonvulsant agents in a population of anticonvulsant new users compared with patients initiating a reference anticonvulsant drug.The study identified 827 suicidal acts (801 attempted suicides and 26 completed suicides) and an additional 41 violent deaths (868 combined suicidal acts or violent deaths) in 297,620 new treatment episodes of anticonvulsant medications.
The risk of suicidal acts was increased for gabapentin (HR=1.42; 95% CI, 1.11–1.80), lamotrigine (HR=1.84; 95% CI, 1.43–2.37), oxcarbazepine (HR=2.07; 95% CI, 1.52–2.80), tiagabine (HR=2.41; 95% CI, 1.65–3.52), and valproate (HR=1.65; 95% CI, 1.25–2.19), compared with topiramate. The analyses including violent death produced similar results. A secondary analysis confirmed the increased risk and identified an excess of 5.6 cases of attempted or completed suicide per 1,000 person-years among new users of gabapentin, 10.0 cases per 1,000 person-years among new users of oxcarbazepine, and 14.1 cases per 1,000 person-years among new users of tiagabine compared with topiramate. Gabapentin users had increased risk in subgroups of younger and older patients, patients with mood disorders, and patients with epilepsy or seizure disorders.
In 2008, FDA mandated warning labels for anticonvulsant agents regarding the increased risk of suicidal thought and behaviors. The decision was based on a meta-analysis not sufficiently large to investigate individual drugs.
“Healthcare providers should carefully assess the risks and benefits of these medications on an individual patient basis to ensure the associated benefits outweigh the risks,” the study’s lead author Elisabetta Patorno, MD, MPH, research fellow at the division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School in Boston, told Formulary. “Those patients that are determined to benefit should be monitored for symptoms that could lead to suicidal risk. Patients should not stop taking these medications but they should discuss any concern with their doctor. Both patients and healthcare professionals should be alert to early symptoms, such as changes in mood or behavior, which might potentially be associated with suicidal risk.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
